Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

AbbVie Inc (NYSE:ABBV)

64.90
Delayed Data
As of 4:00pm ET
 +0.45 / +0.70%
Today’s Change
45.45
Today|||52-Week Range
71.51
+9.55%
Year-to-Date
Biotech Stock Roundup: Biogen Q2 Results Impress, Gilead HCV Franchise Under Pressure
4:03pm / Zacks.com - Paid Partner Content
Biogen Inc: How Double-Digit Growth Got Trumped
Jul 22 / MotleyFool.com - Paid Partner Content
What to Look for When AbbVie (ABBV) Reports Q2 Results
3:14pm / TheStreet.com - Paid Partner Content
3 Healthcare ETFs to Buy as JNJ Beats Q2 Earnings
Jul 21 / Zacks.com - Paid Partner Content
The Drug-Price War Just Took a Big New Twist
10:24am / MotleyFool.com - Paid Partner Content
3 Stocks Driving The Drugs Industry Higher
Jul 21 / TheStreet.com - Paid Partner Content
Experimental Tau Protein Drug Tangled Up in Late-Stage Alzheimer's Study Failure
8:11am / TheStreet.com - Paid Partner Content
Here's Why Myriad Genetics Is Down 26% in 2016
Jul 21 / MotleyFool.com - Paid Partner Content
Buy Gilead Sciences While It's Wallowing
7:36am / TheStreet.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Zafgen, Celgene, Amgen, AbbVie and Biogen
Jul 21 / Zacks.com - Paid Partner Content
Buy Gilead Sciences While It's Wallowing
7:21am / TheStreet.com - Paid Partner Content
These 5 Healthcare Stocks Have Huge Dividend Yields -- Are Any Worth Buying?
Jul 21 / MotleyFool.com - Paid Partner Content
9 Best Stocks for Value Investors This Week
Jul 26 / GuruFocus News - Paid Partner Content
Biotech Stock Roundup: Celgene in Immuno-Oncology Deal, Zafgen Drops Lead Drug
Jul 20 / Zacks.com - Paid Partner Content
Top 10 Dividend Aristocrats to Buy at a Discount Now
Jul 26 / TheStreet.com - Paid Partner Content
Is This Gilead Sciences' Most Underappreciated Drug Candidate?
Jul 18 / MotleyFool.com - Paid Partner Content
AbbVie (ABBV) Q2 Earnings: Will the Stock Pull a Surprise?
Jul 26 / Zacks.com - Paid Partner Content
3 Big Pharma Stocks That Could Raise Their Dividends
Jul 14 / MotleyFool.com - Paid Partner Content
An Investing Overview of the Multiple Sclerosis Market
Jul 26 / MotleyFool.com - Paid Partner Content
3 Dividend Aristocrats to Avoid
Jul 14 / MotleyFool.com - Paid Partner Content
7 Key Figures From Gilead Sciences' Q2 Earnings
Jul 25 / MotleyFool.com - Paid Partner Content
Amgen and Daiichi Sankyo Team Up for Biosimilars in Japan
Jul 14 / Zacks.com - Paid Partner Content
Roche (RHHBY) Misses on Q2 Revenues, New Launches in Focus
Jul 25 / Zacks.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Juno, Amgen, AbbVie, Gilead and CytRx
Jul 14 / Zacks.com - Paid Partner Content
5 Incredibly Cheap Big Pharma Stocks
Jul 25 / MotleyFool.com - Paid Partner Content
Biosimilars set topple two of the world's biggest drug franchises
Jul 14 / FT.com - Paid Partner Content
5 Reasons Biotech Stocks Are Smart Investments
Jul 24 / MotleyFool.com - Paid Partner Content